Radiolabeled somatostatin analogs in prostate cancer

Mathew L. Thakur, H. Kolan, J. Li, R. Wiaderkiewicz, V. R. Pallela, R. Duggaraju, A. V. Schally

Research output: Contribution to journalArticlepeer-review

52 Scopus citations

Abstract

Vapreotide (RC-160), a somatostatin analog, was labeled with 99mTc by a direct method and also by using CPTA [1,4,8,11-tetraazacyclotetradecane] as a bifunctional chelating agent. The labeled compounds were evaluated in nude mice bearing experimental human prostate cancers. In these studies, 111InDTPA-D-Phe-Octreotide (111In-DTPA-octreotide) served as a standard and 99mTc-oxytocin as a receptor-non-specific control. 99mTc-octreotide was also used. The 24 h tumor uptake of 99mTc-RC-160 was nearly 400% higher, (p < 0.05), than that of 111In-DTPA-octreotide and diminished upon receptor blocking. In all tissues except the kidneys, the uptake of 99mTc-RC-160 was also higher than that of 111In-DTPA-octreotide. The uptake of 99mTc-RC-160 was influenced by the amount of peptide injected and the best tumor/muscle and tumor/blood ratios were obtained when only one μg of the peptide (200 Ci/mmol) was administered.

Original languageEnglish (US)
Pages (from-to)105-113
Number of pages9
JournalNuclear Medicine and Biology
Volume24
Issue number1
DOIs
StatePublished - Jan 1997
Externally publishedYes

Keywords

  • Tc labeled octreotide
  • Tc labeled RC-160
  • imaging prostate cancer
  • radiolabeled somatostatin analogs
  • receptor specific peptides in prostate cancer

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Radiolabeled somatostatin analogs in prostate cancer'. Together they form a unique fingerprint.

Cite this